Lennox-Gastaut Syndrome is an indication for drug development with over 20 pipeline drugs currently active. According to GlobalData, preregistered drugs for Lennox-Gastaut Syndrome have a 88.89% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Lennox-Gastaut Syndrome compared to historical benchmarks. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Lennox-Gastaut Syndrome overview
Lennox-Gastaut syndrome (LGS) is a severe form of epilepsy that starts in early childhood, usually before the age of 4 years. It is characterized by multiple and concurrent seizure types, cognitive dysfunction, and abnormal brain electric activity. The seizures are frequent, occurring daily, and difficult to treat with anti-seizure medications. The most common seizure type is tonic seizure, which causes sudden stiffening of the body and often leads to falls and injuries. LGS can be caused by various conditions that affect the brain, such as brain malformations, infections, head trauma, or genetic disorders. However, in about 30% of cases, no cause can be found. LGS has a poor prognosis and often persists into adulthood. Treatment options include a combination of seizure medications, dietary therapy, vagus nerve stimulation, and epilepsy surgery. The goal of treatment is to improve seizure control and quality of life for people with LGS.
For a complete picture of PTSR and LoA scores for drugs in Lennox-Gastaut Syndrome, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
